calcifediol


Also found in: Wikipedia.

calcifediol

 [kal″sĭ-fĕ-di´ol]
25-hydroxycholecalciferol (a form of vitamin D), used in the treatment of hypocalcemia, hypophosphatemia, rickets, and osteodystrophy associated with various medical conditions including chronic renal failure and hypoparathyroidism, administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

cal·ci·di·ol

(kal-sĭ-dī'ol),
First step in the biologic conversion of vitamin D3 to the more active form, calcitriol; it is more potent than vitamin D3.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
These are available as vitamin D analogues (e.g., calcitriol, calcifediol, doxercalciferol, and paricalcitol) and come under pregnancy drug category C.
The usual treatments included esomeprazole 40 mg (1-0-0), Ievothyroxine 50 [micro]g (1-0-0), desvenlafaxine 50 mg (1-0-0), methotrexate (6 tablets on Tuesdays), indometacin 25 mg (1-1-1), folate 5 mg (1 tablet on Wednesdays, Thursdays, and Fridays each), calcifediol (1 blister per month), and golimumab (1 injection per month started on November 26, 2015).
Depending on the testing laboratory, results are measured in nanograms of 25-hydroxyvitamin D (calcifediol) per milliliter of blood, abbreviated ng/mL, or as nanomoles per liter, abbreviated nmol/L.
In 2016, a third study looked at functional status among 200 elderly men and women in a three-armed randomization: a low-dose control group receiving 24,000 IU of vitamin D; 60,000 IU vitamin D3; or 24,000 IU of vitamin plus 300 meg calcifediol.
Effective immediately, Dr Ashfaq will support the company's ongoing adoption of RAYALDEE (calcifediol) extended-release capsules for the treatment of stage 3 or 4 chronic kidney disease (CKD), lead the further development of RAYALDEE for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 5 CKD and vitamin D insufficiency as well as lead the development of ALPHAREN (fermagate) tablets for the treatment of hyperphosphatemia in adults with stage 5 CKD.
In a cohort of 200 community-dwelling men and women, 70 years and older [74], the incidence of falls was higher in the group receiving 60,000 IU vitamin D monthly (equivalent to 2000 IU vitamin D daily) and in the group receiving 24,000 IU vitamin D plus 300 fig calcifediol monthly (equivalent to 800 IU vitamin D plus 10 [micro]g calcifediol daily) than in the group receiving 24,000 IU vitamin D monthly (equivalent to 800 IU vitamin D daily) (incidence 66.9%, 66.1%, and 47.9%, resp.; P = 0.048).
Further testing determined that she had PTH-independent hypercalcemia; parathyroid hormone (PTH) was decreased at 6pg/mL (normal: 10-65 pg/mL), PTHrP was normal at 14 pg/mL (normal: 14-27 pg/mL), calcifediol (25-hydroxyvitamin D) was decreased at 18 ng/mL (deficiency < 20ng/dL; insufficiency: 20-29 ng/mL; optimal [greater than or equal to] 30 ng/dL), and calcitriol (1,25-dihydroxyvitamin D) was elevated at 159 pg/mL (normal: 18-72 pg/mL).
Compared with active vitamin D (calcitriol), 25-hydroxy vitamin D (calcifediol) has a longer plasma half-life and less potency, with fewer effects on hypercalcemia; thus, it has become a crucial agent for vitamin D replacement in CKD patients.
Formulations of vitamin D included cholecalciferol ([D.sub.3]) 400 to 2000 IU/d for 4 months to 5 years or 100,000 to 500,000 IU every 3 to 12 months for 1 to 5 years; calcifediol (25(OH) [D.sub.3]) 600 IU/d for 4 years; and ergocalciferol ([D.sub.2]) 400 IU/d for 2 years or 3000 to 300,000 IU every 3 to 12 months for 10 months to 3 years.
Depending on the testing laboratory, results are measured in nanograms of 25-hydroxyvitamin D (Calcifediol) per milliliter of blood (abbreviated as ng/mL) or as nanomoles per liter (abbreviated as nmol/L).